NOVO-NORDISK A/S-SPONS ADR
NVONYSE🏆 #86 by market capUS Equity
$626.30▼ $44.78 (−7.15%)
Simulated priceTrack NVO
Get earnings, price moves & breaking news on Telegram
24h▼ 7.2%
7d▲ 1489.6%
14d▲ 1372.6%
30d▲ 1273.5%
ytd▲ 1130.9%
1y▲ 1028.3%
🏦Market Cap
$172.30B
Mid Cap
📈Revenue Growth (YoY)
+6.4%
Slowing
📊Gross Margin
80.7%
High
💵FCF Margin
14.8%
Healthy
⚖️P/S Ratio
3.4x
Fair
Otter Score
56
Weak
Trading Snapshot
- Day Range
- $623.65 – $637.89
- 52-Week Range
- $35.12 – $64.16
- Volume
- $5.71B
- Avg Volume
- $4.84B
- Shares Outstanding
- 4.44B
- Next Earnings
- Oct 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $309.06B
- Last Q Revenue
- $78.49B
- P/E Ratio
- 9.7
- P/S Ratio
- 3.4x
- EPS (TTM)
- $26.30
- Dividend Yield
- 4.60%
- Dilution (1yr)
- −0.3%
Why Investors Own NVO
- ✓High-growth profile — revenue up +28.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 27% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
NOVO-NORDISK A/S-SPONS ADR
NVOFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$309.1B▲ +6.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
81.0%▼ −4.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$127.7B▼ −0.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$29.0B▼ −58.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
4.45B▼ −0.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$104.5B▼ −$17.4B YoY
StockOtter · stockotter.spaceAbout NOVO-NORDISK A/S-SPONS ADR
Pharma with leading GLP-1 franchise (Ozempic, Wegovy).
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100
Analyst Price Target
ⓘAverage Target
$752.89
▲ +20.2% Upside
High Target$841.48
Low Target$624.88
Based on 36 analysts
Latest News & Updates
🚀
CNBC·2h ago
NOVO-NORDISK A/S-SPONS ADR tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift NVO price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
NOVO-NORDISK A/S-SPONS ADR announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.